Market capitalization | $536.09m |
Enterprise Value | $1.06b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 8.58 |
EV/Sales (TTM) EV/Sales | 2.81 |
P/S ratio (TTM) P/S ratio | 1.42 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -12.48% |
Revenue (TTM) Revenue | $378.42m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
6 Analysts have issued a Ironwood Pharmaceuticals forecast:
6 Analysts have issued a Ironwood Pharmaceuticals forecast:
Sep '24 |
+/-
%
|
||
Revenue | 378 378 |
12%
12%
|
|
Gross Profit | 376 376 |
13%
13%
|
|
EBITDA | 119 119 |
39%
39%
|
EBIT (Operating Income) EBIT | 117 117 |
39%
39%
|
Net Profit | -2.46 -2.46 |
100%
100%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.
Head office | United States |
CEO | Thomas McCourt |
Employees | 267 |
Founded | 1998 |
Website | www.ironwoodpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.